301015 Stock Overview
Qingdao Baheal Medical INC. engages in research and development, production, and sale of pharmaceutical products.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 3/6 |
Past Performance | 6/6 |
Financial Health | 6/6 |
Dividends | 2/6 |
Qingdao Baheal Medical INC. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥33.16 |
52 Week High | CN¥43.50 |
52 Week Low | CN¥21.40 |
Beta | 0.49 |
1 Month Change | -2.13% |
3 Month Change | -7.53% |
1 Year Change | 27.15% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -40.95% |
Recent News & Updates
Shareholder Returns
301015 | CN Healthcare | CN Market | |
---|---|---|---|
7D | -6.4% | -6.2% | -4.9% |
1Y | 27.1% | -32.2% | -16.6% |
Return vs Industry: 301015 exceeded the CN Healthcare industry which returned -32.2% over the past year.
Return vs Market: 301015 exceeded the CN Market which returned -16.6% over the past year.
Price Volatility
301015 volatility | |
---|---|
301015 Average Weekly Movement | 6.9% |
Healthcare Industry Average Movement | 6.6% |
Market Average Movement | 8.2% |
10% most volatile stocks in CN Market | 11.5% |
10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 301015 has not had significant price volatility in the past 3 months.
Volatility Over Time: 301015's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | 2,642 | Gang Fu | https://www.bahealpharma.com |
Qingdao Baheal Medical INC. engages in research and development, production, and sale of pharmaceutical products. The company offers vitamin D calcium chewable tablets.
Qingdao Baheal Medical INC. Fundamentals Summary
301015 fundamental statistics | |
---|---|
Market cap | CN¥17.19b |
Earnings (TTM) | CN¥650.92m |
Revenue (TTM) | CN¥7.49b |
26.8x
P/E Ratio2.3x
P/S RatioIs 301015 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
301015 income statement (TTM) | |
---|---|
Revenue | CN¥7.49b |
Cost of Revenue | CN¥5.27b |
Gross Profit | CN¥2.22b |
Other Expenses | CN¥1.56b |
Earnings | CN¥650.92m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 23, 2024
Earnings per share (EPS) | 1.24 |
Gross Margin | 29.59% |
Net Profit Margin | 8.70% |
Debt/Equity Ratio | 49.3% |
How did 301015 perform over the long term?
See historical performance and comparison